Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Accured Expenses (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Change in Accured Expenses data on record, last reported at $10.7 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 52.26% year-over-year to $10.7 million; the TTM value through Dec 2025 reached -$9.5 million, up 75.98%, while the annual FY2025 figure was -$9.5 million, 75.98% up from the prior year.
  • Change in Accured Expenses reached $10.7 million in Q4 2025 per COLL's latest filing, up from -$8.1 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $22.4 million in Q4 2024 and bottomed at -$62.9 million in Q3 2024.
  • Average Change in Accured Expenses over 5 years is -$2.7 million, with a median of -$249500.0 recorded in 2022.
  • The widest YoY moves for Change in Accured Expenses: up 1635.09% in 2025, down 2777.73% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $10.8 million in 2021, then rose by 25.76% to $13.6 million in 2022, then crashed by 62.42% to $5.1 million in 2023, then skyrocketed by 339.04% to $22.4 million in 2024, then plummeted by 52.26% to $10.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $10.7 million in Q4 2025, -$8.1 million in Q3 2025, and $5.6 million in Q2 2025.